1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Albert David Ltd

Albert David Ltd

766.00
INR
-15.15
(-1.94%)
39.55EPS
17.72P/E
4.00BMarket Cap
Albert David Ltd
BSE:ALBERTDAVD
(Bombay Stock Exchange)

Recent

price

766.00

P/E

ratio

17.72

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
384.96
400.66
459.59
507.81
561.54
560.79
516.34
501.3
547.92
557.95
431.59
547.43
595.76
631.25
601.43
577.11
638.56
Revenue per Share
19
13.37
15
22.03
24.01
84.1
27.96
17.24
46.68
33.59
38.8
61.78
63.39
132.15
30.14
-2.62
39.55
Basic EPS, GAAP
33.27
-3.2
18.97
22.66
31.75
109.16
-0.36
45.99
52.4
25.98
61.29
51.39
9.25
60.67
-75.86
-64.43
- -
Free Cash Flow per Basic Share
5.23
5.21
5.2
5.24
5.83
11.06
2.15
6.6
6.57
15.57
0.07
6.02
9.02
9.06
11.47
5.02
- -
Dividend per Share
124.25
132.38
142.11
158.3
162.64
239.75
320.67
325.81
368.74
390.38
428.2
489.68
545.93
671.05
687.7
686.04
- -
Book Value per Share
124.25
132.38
142.05
157.11
160.41
236.84
316.95
321.51
364.4
386.48
425.63
482.91
541.62
667.81
685.5
685.02
- -
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Basic Weighted Avg Shares
2,197
2,287
2,623
2,898
3,205
3,201
2,947
2,861
3,127
3,184
2,463
3,124
3,400
3,603
3,432
3,294
3,644
Sales/Revenue/Turnover
8.23
6.54
6.07
7.52
6.8
7.03
7.47
5.5
7.5
8.31
4.49
10.29
10.75
11.4
-0.82
0.04
4.69
Operating Margin (%)
100
98
107
111
154
90
77
84
70
77
82
88
85
68
70
98
97
Depreciation Expense
108
76
86
126
137
480
160
98
266
192
221
353
362
754
172
-15
226
Net Income, GAAP
33.9
32.12
36.06
31.89
32.41
23.84
37.35
37.42
38.57
33.8
19.31
25.45
28.7
22.48
31.82
384.76
19.06
Effective Tax Rate (%)
4.94
3.34
3.26
4.34
4.27
15
5.41
3.44
8.52
6.02
8.99
11.29
10.64
20.93
5.01
-0.45
6.19
Profit Margin (%)
138
124
282
261
331
762
759
825
1,172
1,199
1,424
1,460
2,053
2,726
2,499
2,590
- -
Working Capital
92
- -
80
120
60
- -
- -
- -
- -
14
4
11
6
6
13
4
- -
LT Debt
709
756
811
903
928
1,368
1,830
1,859
2,104
2,228
2,444
2,795
3,116
3,830
3,925
3,915
- -
Total Equity
9.41
6.72
7.32
10.01
10.73
33.81
6.77
5.3
6.58
7.82
3.8
9.64
8.61
8.85
-0.44
-0.11
- -
Return on Invested Capital (%)
10.93
8.22
8.93
11.76
12.04
35.18
8.8
4.75
12.67
8.99
9.6
13.39
12.1
21.5
4.4
-2.12
- -
Return on Capital (%)
16.19
10.42
10.93
14.67
14.96
41.8
9.98
5.33
13.44
8.85
9.48
13.46
12.24
21.72
4.44
-0.38
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
292
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
4
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
4,223
3,350
4,000

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,744
- -
Cash, Cash Equivalents & STI
- -
2,576
- -
Accounts Receivable, Net
- -
339
- -
Inventories
- -
583
- -
Total Current Liabilities
- -
1,154
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
292
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.51%
10.2%
-0.24%
Free Cash Flow
-1,276.1%
43.57%
-15.06%
Net Income, GAAP
3.75%
-3.11%
-108.69%
Sales/Revenue/Turnover
1.05%
6.57%
-4.04%
Total Cash Common Dividend
863.06%
1,693.49%
-56.27%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
894
984
831
749
3,432
2026
706
872
899
859
3,294
2027
1,013
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
33.02
31.67
-16.45
-18.1
30.14
2026
13.91
-5.79
26.81
-37.56
-2.62
2027
56.07
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
11.47
2026
- -
- -
- -
- -
5.02
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Albert David Limited (ALBERTDAVD.NS) manufactures and markets a diverse portfolio of pharmaceutical and personal care products in India. The company offers allopathic formulations including tablets, capsules, syrups, ointments, and injectables across therapeutic areas such as anti-infectives, gastro-intestinal, pain management, vitamins, and dermatology; branded generics and over-the-counter products under brands like Loxof, Pantovel, and Albert David; and consumer healthcare items including soaps, creams, baby care, and oral care products. It operates primarily in India with manufacturing facilities in Kolkata, Ghaziabad, and Mandideep, targeting hospitals, pharmacies, retailers, and institutional customers. Founded in 1938 and headquartered in Kolkata, India, Albert David Limited functions as an integrated player in the pharmaceutical sector, encompassing formulation development, production, and distribution. The company maintains subsidiaries such as Albert David Therapeutics Inc. in the United States for international outreach and focuses on both domestic and select export markets in Asia and Africa. In recent developments, Albert David Limited reported robust financial growth in fiscal year 2025, with consolidated net profit surging 85% year-over-year to INR 25.4 crore for the June quarter, driven by strong domestic branded generic sales; it expanded manufacturing capacity at its Mandideep facility to meet rising demand for formulations; and entered strategic distribution partnerships to bolster its OTC portfolio presence in eastern India. No major acquisitions or name changes occurred in the last two years, but the company announced plans for new product launches in anti-diabetic and cardiovascular segments during 2025. These initiatives reflect ongoing operational enhancements amid favorable industry dynamics.